Skip to main content
Premium Trial:

Request an Annual Quote

Hologic Completes Acquisition of Gen-Probe

NEW YORK (GenomeWeb News) – Hologic has completed its $3.8 billion acquisition of Gen-Probe following approval from Gen-Probe's shareholders yesterday.

Gen-Probe will now become a wholly owned subsidiary of Hologic. Carl Hull, the chairman and CEO of Gen-Probe, will stay with Hologic for at least 15 months to direct the combined diagnostic operations, as the firms previously announced.

Hologic signed the agreement in April to acquire Gen-Probe for $82.75 per share. The firm reiterated today that it expects the deal to be $.20 accretive to its non-GAAP adjusted earnings per share in fiscal 2013. It also said that the combined firm expects to realize around $75 million in cost synergies within three years following closure of the transaction.

As of today, Gen-Probe's shares have ceased trading on the Nasdaq.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.